A pharmaceutical composition, comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound represented by the following structural formula ##STR00001## at least one acidifying agent; and a vehicle base comprising at least one pharmaceutically acceptable non-aqueous solvent. Values and preferred values of the variables in structural formula (I) are defined herein.

An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.

The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.

Disclosed is a topical formulation comprising the herbal extracts Portulaca oleracea extract, Rheum palmatum root extract, Chrysanthemum indicum flower extract, Scutellaria baicalensis root extract Phellodendron amurense bark extract and Sanguisorba officinalis root extract or their active molecules. Disclosed also is a topical formulation comprising Portulaca oleracea extract, Rheum palmatum root extract, Chrysanthemum indicum flower extract, Scutellaria baicalensis root extract and Phellodendron amurense bark extract or their active molecules. Further disclosed are methods of treating or preventing acne, comprising administering the disclosed formulations.

Disclosed is a topical formulation comprising the herbal extracts Portulaca oleracea extract, Rheum palmatum root extract, Chrysanthemum indicum flower extract, Scutellaria baicalensis root extract Phellodendron amurense bark extract and Sanguisorba officinalis root extract or their active molecules. Disclosed also is a topical formulation comprising Portulaca oleracea extract, Rheum palmatum root extract, Chrysanthemum indicum flower extract, Scutellaria baicalensis root extract and Phellodendron amurense bark extract or their active molecules. Further disclosed are methods of treating or preventing acne, comprising administering the disclosed formulations.

The present invention relates to Cutibacterium avidum GENSC01 strain (KCTC 13596BP). The present invention also relates to a composition comprising the strain or its culture, and use thereof. The present invention is effective in improvement, prevention or treatment of atopic dermatitis, acne or skin inflammation by fine dust.

The present invention relates to an antibacterial and biofilm formation-inhibiting composition containing myristoleic acid as an active ingredient, wherein the myristoleic acid has been confirmed to exhibit an antibacterial effect against acne bacterium (Cutibacterium acnes) and Staphylococcus aureus, which cause skin inflammation and trouble, and to effectively inhibit the biofilms of Cutibacterium acnes and Staphylococcus aureus, at a very low concentration, and thus, the composition containing myristoleic acid as an active ingredient can be provided as an antibacterial agent and an anti-biofilm composition, and can be provided as a cosmetic composition for ameliorating skin inflammatory diseases.

The present invention relates to an antibacterial and biofilm formation-inhibiting composition containing myristoleic acid as an active ingredient, wherein the myristoleic acid has been confirmed to exhibit an antibacterial effect against acne bacterium (Cutibacterium acnes) and Staphylococcus aureus, which cause skin inflammation and trouble, and to effectively inhibit the biofilms of Cutibacterium acnes and Staphylococcus aureus, at a very low concentration, and thus, the composition containing myristoleic acid as an active ingredient can be provided as an antibacterial agent and an anti-biofilm composition, and can be provided as a cosmetic composition for ameliorating skin inflammatory diseases.

A cosmetic composition for treating acne includes at least one acne treatment active, for example, salicylic acid or a derivative thereof, which may present in an amount that is greater than 1%, by weight, based on the weight of the sulfate-free cleansing composition, and an aqueous carrier that includes at least one surfactant selected from the group consisting of sarcosinates, betaines, and combinations thereof, at least one solubilizer comprising a polyethylene glycol compound, and water. When the sulfate-free cleansing composition is applied to a keratinous tissue it demonstrates deposition and retention of the beta hydroxy acid on the keratinous tissue after rinsing with water.

The present invention provides a crude extract, fractions and sub-fractions from the seaweed Fucus distichus (FD), method of preparation and its use for inhibiting the growth of microbial cells, particularly bacteria causing acne or nosocomial infections such as MRSA in humans or MRSP in dogs.